BERKELEY, Calif., June 9, 2026 — ResVita Bio, a biotechnology company pioneering a topical cell therapy modality where living, genetically engineered bacteria continuously produce protein therapeutics for skin diseases, today announced the appointment of John D. Doux, M.D., M.B.A., to its Board of Directors.

“We are thrilled to welcome John to our Board as ResVita prepares to enter the clinic with RVB-003 in Netherton Syndrome and expands our continuous protein therapy platform across a broad range of chronic and rare skin diseases,” said Amin Zargar, Ph.D., Chief Executive Officer and Co-Founder of ResVita Bio. “John is a respected voice in rare skin disease drug development who has spent years championing the case that the orphan disease model can be applied broadly across dermatology, and that thesis is precisely what our platform is built to deliver. His guidance will be invaluable as we build a pipeline of disease-modifying therapies for patients who have long been overlooked.”

Dr. Doux is a board-certified dermatologist, a Fellow of the American Academy of Dermatology, and a longstanding advocate for advancing novel therapies in rare skin diseases. He serves as an analyst at Palo Alto Investors LP, a physician-led healthcare-focused investment firm, where he has been involved in investments across multiple companies developing and commercializing therapies for rare and serious diseases. Dr. Doux currently serves as a board director for Palvella Therapeutics (Nasdaq: PVLA) and Orvida Pharma (formerly Kamari Pharma), and also serves as a board trustee for the Pachyonychia Congenita Project. He co-founded the Dermatology Summit and the Dermatology Innovation Forum and previously served on the conference’s Board of Directors. He maintained a clinical practice in medical and surgical dermatology from 1999 to 2016.

“ResVita has built a true platform where genetic sequences can be swapped to direct the continuous, local production of different therapeutic proteins at the skin surface,” said Dr. Doux. “That modularity, combined with the platform’s preclinical safety and delivery profile, uniquely positions the company to develop disease-modifying therapies for many rare skin diseases with no approved treatments and profound unmet need. I am pleased to join the Board as ResVita advances RVB-003 toward the clinic, and I look forward to partnering with Amin and the team to help bring these therapies to patients.”

Dr. Doux received his B.S. with Distinction and M.D. from Stanford University and conducted early dermatology research as a Howard Hughes Medical Institute Student Fellow in the laboratory of Dr. David T. Woodley. He completed his internship in internal medicine at Brigham and Women’s Hospital and his dermatology residency at Stanford University Medical Center, where he served as Chief Resident. He also earned an M.B.A. from The Wharton School of the University of Pennsylvania, where he was named a Palmer Scholar.

About ResVita Bio

ResVita Bio is a therapeutics company based in Berkeley, California, developing topical cell therapies for skin diseases. By harnessing genetically engineered, non-pathogenic bacteria to continuously produce therapeutic proteins directly on the skin, ResVita is building a pipeline of disease-modifying therapeutic candidates for patients with serious skin diseases. The Company’s lead investigational therapy, RVB-003, is being developed for Netherton Syndrome, a chronic and life-threatening genetic skin disorder with no FDA-approved therapies, and has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. This work was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awards 1R43AR082240-01 and 2R44AR082240-02.

Media Contact:

Amin Zargar

510-458-2297

[email protected]

SOURCE ResVita Bio

S3 Ventures & Brick & Mortar Ventures lead Series A as Earlytrade posts 7X US revenue growth; Scott Wolfe, founder of Levelset, joins board

DENVER, June 9, 2026 — Earlytrade, the global fintech platform transforming working capital management for the construction industry, today announced new funding bringing total raised to $25 million, including its Series A round led by S3 Ventures and Brick & Mortar Ventures. Capital is being deployed across two priorities: expanding Earlytrade’s US commercial operations and building agentic AI into the core marketplace infrastructure.

Earlytrade operates a subcontractor payments marketplace that allows general contractors to dynamically trade working capital with their subcontractor base, giving them the ability to secure their supply chains and ensure project outcomes are delivered. Since launching in the US in 2024, the company has achieved 7X revenue growth, grown its network to over 211,000 subcontractors, and facilitated more than $3 billion in early payments globally.

“Every dollar that flows through a construction project passes through a payment bottleneck that has never been solved at scale. Earlytrade has built the infrastructure layer that makes agentic AI in this space possible,” said Charlie Plauche, General Partner at S3 Ventures. “That combination of a proven two-sided marketplace and a genuine AI deployment path is exactly what we look for when we back a category-defining company.”

The US construction industry generates over $2 trillion in output annually, yet subcontractors, who perform the majority of the work, routinely wait 60 to 90 days for payment, creating chronic working capital strain. Earlytrade’s subcontractor payment marketplace addresses this structural disadvantage directly, giving subcontractors control over when and at what rate they access capital already owed to them.

“Subcontractors value having flexibility in how and when they access capital to support their businesses,” said Dave Anderskow, CFO at Power Construction, a general contractor and client of Earlytrade. “Earlytrade’s marketplace allows us to invest in our trade partners’ growth in a way that is both disciplined and sustainable.

Founded in 2018 in Australia, Earlytrade relocated its incorporation to the US this year, protecting investors from an increase in capital gains tax that would have doubled their tax burden.

“Strong US growth has made one thing clear: the time is right to make a significant investment in agentic AI within our subcontractor payments marketplace,” said Guy Saxelby, CEO and Co-founder of Earlytrade. “We’re actively seeking exceptional talent across AI, Product, and Sales. Visit our careers page to learn more.”

Joining the board alongside Plauche are Darren Bechtel of Brick & Mortar Ventures; Scott Wolfe, founder and former CEO of Levelset, which sold to Procore for $500 million; Kevin Halter, former revenue leader at PlanGrid who helped scale revenue from $5 million to $90 million before a $900 million acquisition by Autodesk; and Ben Brahinsky, an M&A and private equity specialist who has advised the Earlytrade board for two years and sits on more than ten construction industry boards.

For more information on Earlytrade and available career opportunities, visit www.earlytrade.com.

About Earlytrade

Earlytrade is a global fintech company transforming how construction and enterprise businesses grow margin and turn finance operations into a profit center. Operating across Australia, New Zealand, the United States, Canada, Ireland, and the United Kingdom, Earlytrade’s suite of solutions, including early payment and progress claim platforms, empowers general contractors and trade partners to improve cash flow, increase profitability, and build more resilient supply chains. Learn more at earlytrade.com.

Media Contact:
Stephanie Hall
Pitch Public Relations
480.363.5371
[email protected]

SOURCE Earlytrade

Financing round led by new investor Viking Global Investors with participation from key existing investors

TEMPE, Ariz., June 9, 2026 — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced the closing of an oversubscribed $100 millon Series E equity financing. The financing was led by new investor Viking Global Investors with participation from key existing investors, including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.

“This financing is validation of GammaTile’s potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients,” said Per Langoe, Chief Executive Officer at GT Medical Technologies.

The funds will be used to accelerate investments across commercial and operational initiatives following the release of the final data from the Company’s ROADS randomized controlled trial (RCT) last month. The ROADS RCT studied the use of GammaTile^®, the Company’s FDA-cleared bioresorbable radiotherapy implant, in patients with newly diagnosed brain metastases. The ROADS RCT data was selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) conference and demonstrated statistical superiority for GammaTile relative to standard of care; GammaTile reduced the risk of tumor recurrence and death at 12 months by 93% and 41%, respectively.¹

Proceeds from the financing will also support continued expansion of GT Medical Technologies’ recently initiated BRIDGES RCT in patients with newly diagnosed glioblastomas (GBMs).

“We are excited to lead this financing and to work with GT to unlock the potential of GammaTile therapy,” said Jason Rostovsky, a Principal at Viking Global Investors. “GT Medical Technologies’ technology has demonstrated profound clinical impact, and we look forward to supporting the GT Medical Technologies team in improving the treatment algorithm for patients with resectable brain tumors.”

“An oversubscribed financing of this magnitude and the strength of our syndicate provides significant optionality for the Company, allowing us to accelerate the next phase of our growth and make meaningful clinical and operational investments for the future,” added James Leech, Chief Financial & Strategy Officer at GT Medical Technologies.

GammaTile is an innovative form of radiation therapy placed at the time of brain tumor removal surgery, delivering immediate, targeted radiation to the tumor resection site when cancer cells are at their lowest residual levels. Unlike conventional approaches that require delays between surgery and the initiation of radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap by starting treatment immediately. By delivering immediate, concentrated radiation directly at the tumor site, GammaTile maximizes the treatment’s effectiveness against remaining cancer cells and reduces the risk of regrowth.

ROADS RCT data presented at the 2026 ASCO conference demonstrated that the 12-month rate of tumor surgical bed recurrence was dramatically lower with GammaTile at 1.3% compared with standard of care at 15.4% (HR:0.07, p=0.012).¹ Surgical bed recurrence-free survival, defined as the time from surgery to either tumor recurrence or death from any cause, whichever occurred first, was significantly improved with GammaTile, with the median time to an event not reached compared with standard of care at 10.9 months (HR: 0.48, P=0.002).¹ Additionally, 24-month overall survival was 61.7% for GammaTile compared with 35.7% for standard of care (HR: 0.59, p=0.032).¹

Recent GT Medical Technologies Milestones

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile^® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases

Radiation-emitting implant improves outcomes after brain cancer surgery | Reuters

GT Medical Technologies Announces First Patients Treated with GammaTile in the BRIDGES Trial for Newly Diagnosed Glioblastoma

https://www.prnewswire.com/BRIDGESgammatile

About GT Medical Technologies, Inc.

GT Medical Technologies was founded by a dedicated team of tumor specialists to address unmet needs in brain tumor treatment. The Company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About Viking Global Investors 

Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages $52 billion of capital across public and private investments. Viking has offices in Stamford, New York, Hong Kong, London, and San Francisco, and is registered as an investment adviser with the U.S. Securities and Exchange Commission. For more information, please visit www.vikingglobal.com. 

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations, beliefs, or projections. These forward-looking statements are based on management’s current expectations and involve significant risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Such factors and risks which could cause actual results to differ materially from those in the forward-looking statements include, without limitation: regulatory risks such as changing CMS, NRC, FDA rules and regulations impacting clearance and/or reimbursement of indicated products; supply chain disruptions; clinical trial and investigation risks including adverse patient outcomes such as death and other severe complications; cost of capital and inflationary risk of raw materials; legal and regulatory risks associated with potential mergers, acquisitions, investments in joint ventures; other global and regulatory uncertainties. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Reference:
1. Weinberg J. ROADS: A randomized controlled phase 3 trial of resection plus post-operative stereotactic radiation versus resection plus cesium-131tile-based radiation therapy for newly diagnosed brain metastases. Presented at: 2026 American Society of Clinical Oncology Conference; May 30, 2026; Chicago, IL.

Media Contact:
Dawn Fallon
New Dawn Communications
[email protected]
(732) 771-7808

SOURCE GT Medical Technologies

Series E Financing Reflects Sustained Investor Confidence in CeQur’s Commercial Trajectory, Clinical Results, and Growing Demand for a Simpler Approach to Mealtime Insulin

HORW, Switzerland, June 9, 2026 — CeQur, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced the close of a $100 million Series E financing round. The investment reflects sustained investor confidence in CeQur’s commercial trajectory, its strong pipeline, and the growing demand for a simpler approach to mealtime insulin. The Series E reflects CeQur’s momentum and marks the beginning of its most ambitious phase of commercial growth.

The $100 million will accelerate growth across every dimension of the commercial operation, and CeQur has the infrastructure to deploy it. The field sales team will expand, deepening relationships with healthcare providers and diabetes care specialists who are looking for a simpler approach to mealtime insulin for their patients. As CeQur Simplicity expands to include extended 7-day wear and both 1-unit and 2-unit options, the company is positioned to meet demand across a broader and growing patient population.

“We have the commercial infrastructure, new clinical evidence. and an exciting pipeline. Now we have the capital to accelerate our growth,” said Bradley Paddock, President and Chief Executive Officer of CeQur. “CeQur Simplicity is ready to reach every patient and physician who wants to simplify their insulin delivery and improve their diabetes management.”

Adoption of CeQur Simplicity is expanding steadily across primary care and endocrinology practices nationwide. Better than 85% of all claims are covered as a pharmacy benefit, with an average copay of less than $45 per month. Clinically, the evidence is equally compelling: nearly 90% of patients reported following their insulin regimen better with CeQur Simplicity¹ compared to multiple daily injections, with significantly improved A1C² and time-in-range outcomes³.

“This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur’s growth trajectory,” said Mike Rubino, Chief Financial Officer of CeQur. “We are grateful for that trust and committed to deploying this capital to deliver on the full potential of CeQur Simplicity for patients, for providers, and for every investor who believes in our mission.”

With new FDA clearances, compelling clinical data, and $100 million in capital, CeQur Simplicity is positioned to ensure that patients who want a simpler approach to insulin delivery have options.

About CeQur Simplicity^™

CeQur Simplicity is a convenient, discreet, and injection-free wearable insulin patch that simplifies mealtime dosing. The patch is clinically proven to improve glycemic control, with patients achieving significantly improved A1C² and time-in-range goals³. For people over 21 years of age with diabetes.

Learn more at MyCeQurSimplicity.com or call 1-888-55-CEQUR.

About CeQur^®

CeQur commercializes advanced, simple-to-use insulin-delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease. The Company’s simple, wearable devices provide freedom from multiple daily insulin injections.

1. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at: American Diabetes Association 76th Scientific Sessions; 2016; New Orleans, LA. Abstract 995-P.
2. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
3. Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; Journal of Diabetes Science and Technology 1–7, 2021

SOURCE CeQur Corporation

GWACHEON, South Korea, June 8, 2026 — Park Systems Corp. (KOSDAQ: 140860), a global leader in atomic force microscopy (AFM) and nanometrology, today announced the successful completion of a KRW 100 billion (approximately USD 72 million) strategic financing through the issuance of perpetual bonds with warrants, with Kiwoom Securities and Dominus Investment Management each subscribing KRW 50 billion. The proceeds will support the company’s production capacity expansion and broader strategic initiatives as demand for precision nanometrology continues to grow across the semiconductor and advanced materials industries.

The bonds were issued at par with 0% interest for the first three years, followed by a step-up interest structure. Warrants are exercisable from June 8, 2027 to May 8, 2056 at KRW 267,747 per share, and Park Systems retains a call option to repurchase up to 20% of the bonds at par between June 2027 and June 2029.

“This financing reflects the company’s commitment to scaling its manufacturing infrastructure in alignment with increasing market demand,” said Karen Cho, Senior Executive Vice President at Park Systems. “As semiconductor process nodes shrink and advanced packaging architectures grow more complex, the need for sub-nanometer surface metrology has become critical across front-end and back-end semiconductor manufacturing. We believe this investment will strengthen our ability to meet growing customer demand and better serve customers worldwide.”

Park Systems serves leading global chipmakers and research institutions across more than 30 countries. Building on this momentum, Park Systems reported consolidated revenue of KRW 205.6 billion in 2025. With a diversified customer base that includes major semiconductor manufacturers and a growing installed base in academic and industrial research, the company is well-positioned to capitalize on the continued expansion of nanotechnology applications worldwide.

About Park Systems

Park Systems is a global leader in nanometrology, providing advanced measurement solutions for both research and industrial applications. Founded by Dr. Sang-il Park, a contributor to the invention of atomic force microscopy (AFM) at Stanford University, the company has grown through continuous innovation and strategic acquisitions to become a leading force in the global nanometrology industry. Park Systems’ technology portfolio includes AFM, white light interferometry (WLI), digital holographic microscopy (DHM), imaging spectroscopic ellipsometry (ISE), active vibration isolation systems, and solid metal probes. With regional offices across the Americas, Europe, and Asia, Park Systems supports customers in semiconductor manufacturing, materials science, and nanotechnology research.

For more information, visit www.parksystems.com

SOURCE Park Systems Corp.

Led by CoinFund, the investment will support the launch of EDGE Pro, a dedicated banking platform for market makers trading on prediction markets, and EDGE Connect; the first purpose-built payment rail for gaming and prediction markets

NEW YORK, June 8, 2026 — EDGE Markets, a financial services company that creates products for alternative financial markets in the gaming, crypto, and prediction markets space, announced today that it closed a $29.2 million Series A round. CoinFund led the round, alongside Indicator Ventures, Mantis VC, Stepstone Group, and Bullpen Capital.

With this funding, EDGE Markets is expanding its offerings to introduce EDGE Pro, the first high throughput deposit accounts for market makers that enable seamless, real-time deposits into all CFTC regulated exchanges. EDGE Pro solves the two largest friction points for institutional capital to scale: multi-liquidity pool post-execution settlement and margin. To enable this solution, EDGE Markets is actively pursuing both an Introducing Broker and Future Commission Merchant registrations with the National Futures Association. These registrations will allow EDGE Pro users to execute orders directly through their EDGE Pro accounts and conduct post-execution settlement across various liquidity pools to dramatically amplify capital efficiencies vs. the current model where all trading accounts need to be prefunded and fully collateralized. Finally, EDGE Pro users will be able to plug and play existing margin from third party prime brokerages. To sign up for early access to EDGE Pro, market makers can visit www.edgemarkets.io/pro.

“The core vision of EDGE Markets has always been to decrease friction for capital to flow in regulated markets. With the high velocity growth of prediction markets, we are excited to build and support the core infrastructure for traders to efficiently scale their activity. There are many talented groups building exchanges, but we’re building the base station for capital allocation, to address their real needs,” said Seni Thomas, Founder and CEO of EDGE Markets.

The new funding will also go towards launching EDGE Connect; the industry’s first purpose-built payment rail, engineered specifically for the regulated gaming and prediction market ecosystems. EDGE Connect will replace traditional consumer rails with a real-time network that will deliver significantly lower transaction costs for operators by only charging a fee on Net New Deposits over a 24-48 hour period. EDGE Connect significantly reduces churn costs, eliminates chargebacks, and provides users with a faster, more secure experience. Back testing with major operators has shown a 70%+ cost reduction in payment processing fees. EDGE Connect also supports high throughput Real Time Payments (RTP) at no cost for EDGE users or operators to push funds into their accounts 24/7/365. RTP is supported by the majority of banks in the US and requires no integration from operators. To support the early growth of the prediction market ecosystem, both EDGE Connect for operators and EDGE Pro for market makers will be provided at no cost for all early users and operators in 2026.

“The biggest moments in gaming and prediction markets happen on nights and weekends, exactly when the banking system slows to a crawl. EDGE built the rails to match that reality. And, as institutions start to participate in these markets seriously, the ability to move capital in size, in real time, any day of the week, stops being a nice-to-have and becomes table stakes. We think EDGE becomes the default settlement layer for an entirely new category of financial markets,” said Alex Felix, Co-Founder, Managing Partner and CIO of CoinFund.

Since its launch a year ago, EDGE Markets’ VISA debit program, EDGE Boost, has processed over two billion dollars in transactions to date, making it one of the fastest growing debit cards in the history of VISA. The company has also partnered with ZeroHash to introduce a compliant crypto-to-USD conversion path for users, ensuring a seamless ability to access funds. As the only banking platform dedicated to the gaming and prediction market industries, EDGE Boost offers instant access to funds with no hidden fees, or pain points associated with gaming and traditional banks. EDGE Boost separates these funds from every day finances and gives users tools to track and control their spending across multiple operators. Proprietary research conducted by EDGE Boost in partnership with Betting Hero found that 85% of high-value gaming users expressed interest in a financial product tailored specifically to gaming.

About EDGE Markets
EDGE Markets is a U.S. banking solution that empowers users with financial transparency, supporting emerging verticals such as betting, gaming, and casinos. Its original product, EDGE Boost, is the first responsible financial platform for smart bettors. It is the first betting-only debit card account that is FDIC insured up to $250,000. Deposit accounts are held at Cross River Bank, Member FDIC, and are insured up to $250,000 per depositor. Through our relationship with IntraFi® Network Deposits^SM, funds may be eligible for additional FDIC insurance coverage by being distributed across participating network banks – up to $10,000,000 in aggregate for consumer accounts enrolled in the applicable program. FDIC insurance coverage is subject to applicable terms and conditions, including account structure, account ownership categories, and regulatory requirements. The EDGE Boost Visa® Debit Card is issued by Cross River Bank, Member FDIC, pursuant to a license from Visa U.S.A. Inc., and is not available to all residents of U.S. territories. Account limits and other applicable terms are described in our Terms of Service and Cardholder Agreement and CRB Account Agreement.

About CoinFund
CoinFund is one of the world’s first blockchain-native venture firms, dedicated to furthering the future of decentralized networks. CoinFund partners deeply with the founders building blockchain’s most important companies, offering technical insight, strategic guidance, and the credibility of a venture firm deeply rooted in the ecosystem

Media Contact 
Justine Sacco / [email protected]
[email protected]

SOURCE EDGE Markets

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, June 8, 2026 — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on June 8th

• Equities are higher Monday morning, even as tensions in the Middle East remained elevated over the weekend.
• PointFive’s Co-Founder and CPO Gal Ben David will join NYSE Live to disclose how the company will allocate $60 million in fresh capital.
• Man Group’s CEO Robyn Grew will join Taking Stock to discuss the firm’s first two active ETFs, which recently began trading on NYSE Arca.
• SEC Chairman Paul Atkins and NYSE Head of U.S. Listings Tara Dziedzic will speak at NIRI 2026 in Chicago, connecting key decision-makers in the IR community

Opening Bell
Colgate-Palmolive (NYSE: CL) celebrates its 220^th anniversary of founding

Closing Bell
Man Group ETFs celebrates the launch of its first two active ETFs

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

SOURCE New York Stock Exchange

Moonshots Capital leads round along with prominent angel investors

AUSTIN, Texas, June 8, 2026 — InfoHawk, the AI platform built to detect and neutralize deception at internet scale, today announced it has closed a $2.25 million pre-seed financing round, led by Moonshots Capital. InfoHawk was founded by Rob Leathern, Ben Poiesz, and Jamie McCrindle.

Fraud and scams have grown from an internet nuisance into one of the defining threats of the digital age. If scams were a country, it would rank around 30th in the world by GDP — bigger than Austria, Colombia, or Singapore. Consumers globally lost an estimated $442 billion to scams in 2025 (GASA.org). And the global trade in counterfeit goods is estimated at an additional $467 billion per year.

AI tools are supercharging scams, by making them faster & more automated, allowing fraudsters to easily copy legitimate sites, videos or assets in seconds. Brands are being impersonated, and enterprise employees are being deepfaked or their accounts compromised.

Scammers operate across jurisdictions and platforms, making attribution and enforcement nearly impossible without specialized intelligence and infrastructure. The result is a fraud ecosystem that is faster, cheaper, and harder to detect than ever before.

InfoHawk is Tackling These Problems

InfoHawk detects, analyzes and neutralizes online deception at scale. Delivered by highly performant APIs, InfoHawk’s software combines advanced content detection with deep infrastructure mapping to help enterprises protect their users from online scams and digital fraud.

InfoHawk’s financing round was led by Moonshots Capital, a seed-stage venture firm:

“We invest in extraordinary leaders solving hard problems, and InfoHawk fits that bill perfectly. Rob, Ben, and Jamie bring two decades of experience from inside the largest platforms. They understand both how this ecosystem works and how to break it for the bad guys. With AI now turbocharging scams, InfoHawk is building exactly the kind of independent, data-driven infrastructure the internet needs.”
          — Kelly Perdew, Founding Partner, Moonshots Capital

Moonshots is joined by angel investors with experience building, defending, and regulating at-scale online platforms. Investors in this round include former two-term Chairman of the Federal Trade Commission, Jon Leibowitz, as well as Brian O’Kelley (founder of AppNexus), Rob Goldman (former head of Ads at Meta), James Walker (founder and CEO of Centigrade), Scott Spencer (former VP of ads safety and privacy at Google), Vlad Fedorov (CTO of GitHub), Nikila Srinivasan (former VP of Product for WhatsApp) and others.

About Moonshots Capital
Moonshots Capital is an early-stage venture firm investing in extraordinary leadership building category-defining companies across critical technology sectors, including dual-use, cybersecurity, fintech, AI, and defense innovation. Founded in 2014 by West Point graduates and military veterans Kelly Perdew and Craig Cummings, Moonshots has backed 131 companies to date, with 33 exits and 18 unicorns. Learn more at: https://moonshotscapital.com

About InfoHawk
InfoHawk is an AI platform built to detect, analyze, and neutralize online deception at internet scale. Contact: Rob Leathern, (571) 736-2469, or https://infohawk.com

SOURCE InfoHawk

Mehr als 138 000 Bewerber aus über 40 Ländern nutzten KI-gestützte Tools und Vibe Coding, um über Red Bull Basement Startup-Ideen zu entwickeln.

SAN FRANCISCO, 6. Juni 2026 — Red Bull Basement verlieh Darnell Adler (Vereinigte Staaten) und seinem Unternehmen Lifeline AI in San Francisco den Titel beim World Final 2026, womit sie 100.000 US-Dollar als Finanzierung ohne Abgabe von Unternehmensanteilen, 25.000 US-Dollar an Microsoft-Azure-Guthaben sowie Mentoring durch Red Bull Ventures erhalten. Der globale Startup-Wettbewerb zog mehr als 138 000 Bewerbungen aus über 40 Ländern an und ist damit die bisher größte Austragung von Red Bull Basement.

Das Siegerprojekt, Lifeline AI, ist eine Plattform für persönliche Sicherheit, die stille Notfallalarme ermöglicht, ohne ein Telefon sichtbar zu entsperren, eine Nummer zu wählen oder zu sprechen. Das System soll Nutzern helfen, Notfälle diskret zu melden, wenn sichtbare Interaktion das Risiko erhöhen oder die Hilfe verzögern könnte.

Red Bull Basement soll Erstgründern und Unternehmern im Studium helfen, ihre Ideen zu funktionierenden Produkten und Unternehmen zu machen. Über den eigentlichen Wettbewerb hinaus erhalten die Teilnehmer Zugang zu KI-gestützten Entwicklungstools, Mentoring, Startup-Schulungen sowie Möglichkeiten, ihre Ideen zu verfeinern, bevor sie sie auf einer globalen Bühne präsentieren.

Während des gesamten Programms nutzten die Gründer Vibe Coding – also die Entwicklung von Software durch Anweisungen in natürlicher Sprache statt durch herkömmliche Programmierung –, funktionsfähige Minimalprodukte (MVPs) zu erstellen und zu verfeinern. Der Ansatz senkt die technischen Hürden für Gründungen und versetzt die Teilnehmer in die Lage, Software zu entwickeln, Ideen zu testen und Unternehmen zu gründen, ohne einen Hintergrund in der Softwareentwicklung zu benötigen.

Der Wettbewerb richtet sich an angehende Gründer in der frühesten Phase ihres Gründungswegs. Die Teilnehmer brauchen weder ein etabliertes Unternehmen noch einen technischen Hintergrund noch einen Mitgründer, um teilzunehmen. Einzelpersonen und Teams können ihre Ideen mithilfe von KI-gestützten Tools und der während des Wettbewerbs bereitgestellten Anleitung zu funktionierenden MVPs entwickeln.

Im Gegensatz zu vielen Startup-Wettbewerben verlangt Red Bull Basement in keiner Phase Unternehmensanteile von den Teilnehmern. Die Gründer behalten alle Rechte an ihren Ideen und erhalten zugleich durch den Wettbewerb Zugang zu Mentoring, Technologieressourcen, Branchenexperten sowie Finanzierungsmöglichkeiten.

„Ich habe immer noch keine Worte dafür, ich zittere”, sagte Darnell Adler, Gründer von Lifeline AI und Gewinner des Red Bull Basement World Final 2026. „Der globale Gewinner von Red Bull Basement zu sein, bedeutet, dass ich Menschen in großem Maßstab helfen kann. Lifeline AI wird die Welt zu einem sichereren Ort machen.”

Das World Final 2026 war die erste Austragung von Red Bull Basement in den Vereinigten Staaten. Da KI-gestützte Tools die Hürden für Gründungen weiter senken, bietet Red Bull Basement angehenden Gründern einen Weg, Ideen zu testen, MVPs zu entwickeln und um Finanzierung zu konkurrieren, ohne dass sie einen Mitgründer, ein etabliertes Unternehmen oder einen Hintergrund in der Softwareentwicklung benötigen.

SI/MI-Materialien über den Red Bull Content Pool herunterladen: redbullcontentpool.com/redbullbasementWF2026
Weitere Informationen für Medien: https://www.redbullcontentpool.com/international/CP-S-20949
Medienkontakt: [email protected]

Foto – https://mma.prnewswire.com/media/2995546/Red_Bull_Basement_World_Final_Darnell_Adler.jpg
Foto – https://mma.prnewswire.com/media/2995547/Red_Bull_Participants.jpg
Logo – https://mma.prnewswire.com/media/2818025/6004497/Red_Bull_Logo.jpg